# Milestone (MIST) — News

MIST · NASDAQ · Stock

Canonical page: https://www.lighthorse.io/tickers/mist/news

## Recent headlines

- [MIA Teknoloji - Company expects to generate about 21.6 mln lira in revenue from agreement](https://www.ainvest.com/news/mia-teknoloji-company-expects-generate-21-6-mln-lira-revenue-agreement-2610) — AInvest Wire, Oct 15, 2026
  Mia Teknoloji A.Ş. (MIATK) is anticipated to generate approximately 21.6 million Turkish lira in revenue from a recent agreement, according to available data. The company has been actively expanding its operations through strategic partnerships and project developments, including a recent…
- [Milestone Pharmaceuticals announces NMPA approval of Etripamil nasal spray for PSVT in China, marking first regulatory approval of Etripamil outside of the United States](https://www.ainvest.com/news/milestone-pharmaceuticals-announces-nmpa-approval-etripamil-nasal-spray-psvt-china-marking-regulatory-approval-etripamil-united-states-2609) — AInvest Wire, Sep 3, 2026
  Milestone Pharmaceuticals Inc. (Nasdaq: MIST) announced that the National Medical Products Administration (NMPA) in China has accepted the New Drug Application (NDA) for etripamil nasal spray for the treatment of paroxysmal supraventricular tachycardia (PSVT) . This marks the first regulatory…
- [Everest Medicines - NMPA approves Cardamyst (Etripamil) NDA for PSVT in adults in China](https://www.ainvest.com/news/everest-medicines-nmpa-approves-cardamyst-etripamil-nda-psvt-adults-china-2609) — AInvest Wire, Sep 3, 2026
  Milestone Pharmaceuticals Inc. (Nasdaq: MIST) announced that Everest Medicines, its licensing partner in Greater China, has received approval from the National Medical Products Administration (NMPA) for the New Drug Application (NDA) of CARDAMYST™ (etripamil) nasal spray for the treatment of…
- **Important** — Milestone Pharmaceuticals shares sank 28% after receiving rejection from FDA — AInvest Wire, Dec 26, 2023
  Milestone Pharmaceuticals shares sank 28% after receiving rejection from FDA Milestone Pharmaceuticals, a biopharmaceutical company, announced the submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for etripamil for the treatment of paroxysmal supraventricular…
- Milestone Pharma resumes trading, drops 41% premarket on FDA saying NDA, submitted in Oct. 2023 not sufficiently — AInvest Wire, Dec 26, 2023

---

Light Horse does not author, endorse or verify the headlines, and their appearance here is not an endorsement of any view they express.

This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.

Data provided by [AInvest](https://www.ainvest.com).